OPKO Health, Inc. (0KCS.L)
| Previous close | 1.3100 |
| Open | 1.3350 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 1.2903 - 1.3400 |
| 52-week range | 0.8516 - 2.2315 |
| Volume | |
| Avg. volume | 114,049 |
| Market cap | 6.118M |
| Beta (5Y monthly) | 1.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1790 |
| Earnings date | 07 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireOPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024
MIAMI, May 03, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2024 after the close of the U.S. financial markets on Tuesday, May 7, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on May 7th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participant
ZacksOPKO Health (OPK) to Restructure After Asset Buyout by Labcorp
OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.
- Zacks
Labcorp (LH) to Boost Clinical Diagnostics With New Deal
The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.
